Verastem, Inc.

NASDAQ:VSTM

Biotechnology

Healthcare
$6.87 -0.00%

-$0.00 today

Market cap
$865.72M
Beta
0.27
P/E (TTM)
-2.1
EPS (TTM)
-$1.97
52W Low $3.55High $11.25

Volume 3.97M

Average 2.58M

VSTM Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Verastem, Inc.NASDAQ: VSTM

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables rises 5079.0% from a year ago

Net receivables stood at $10.36M at the end of Q1 FY2026, up 5079.0% from a year earlier and up 5079.0% from the prior quarter. Over 3 fiscal years it compounded at +557.5% a year.

Context

  • Net receivables amounted to 4.5% of total assets at the end of Q1 FY2026, up 4.4 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +5079.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.36M+5079.0% QoQ
Last fiscal yearDec 2025
$8.81M+4306.5% YoY
Year agoMar 2025
$200K+5079.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5079.0%——
1 year+4306.5%——
3-year CAGR+557.5%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
8.81M USD
Year-over-year change
+4306.5%
4-year CAGR
+103.3%

Net Receivables vs competitors

How VSTM compares with its peers on the latest reported figures

  • VSTM's Mar 2026 net receivables of $10.36M is the 2nd highest of the 11 companies compared; the peer median is $73K.
  • Its year-over-year change of +5079.0% is the highest of 6, against a peer median of +18.4%.
  • Net receivables amounts to 4.5% of total assets for VSTM, versus a peer median of 0.0%.
VSTM Competitors Peer median
Net Receivables for VSTM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NUVBNuvation Bio Inc.Jun 2026$31.71M +375.0%+98.2%4.3%
VSTMVerastem, Inc.Mar 2026$10.36M +5079.0%+557.5%4.5%
CCCCC4 Therapeutics, Inc.Mar 2026$2.88M -64.1%+17.7%0.9%
ANLAdlai Nortye Ltd.Dec 2025$1.39M +18.4%+59.0%4.0%
CRDFCardiff Oncology, Inc.Mar 2026$191K -52.8%-38.2%0.4%
BBOTBridgeBio Oncology Therapeutics Inc.Mar 2026$146K +265.0%—0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
PRLDPrelude Therapeutics IncorporatedMar 2026$0 ——0.0%
IMRXImmuneering CorporationMar 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.Mar 2026$0 ——0.0%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding VSTM) $73K+18.4%+38.3%0.0%

Competitors are the stored peer set for VSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents21.25M74.93M77.91M88.82M204.99M
Short-term Investments79M12.96M59.22M00
Net Receivables516K31K0200K8.81M
Inventory00001.83M
Other Current Assets006.55M5.94M7.78M
Total Current Assets105.74M92.87M143.68M94.96M223.41M
Property, Plant & Equipment (Net)2.51M1.88M1.21M1.44M491K
Goodwill00000
Intangible Assets000016.43M
Long-term Investments0241K000
Tax Assets00000
Other Non-current Assets410K58K4.83M5.14M6.11M
Total Non-current Assets2.92M2.18M6.04M6.58M23.03M
Total Assets108.66M95.05M149.72M101.54M246.44M
Account Payables2.3M4.9M7.18M4.03M12.45M
Short-term Debt0275K00535K
Tax Payables00000
Deferred Revenue0710K000
Other Current Liabilities3.89M11.14M5.12M6.25M59.29M
Total Current Liabilities18.59M21.66M26.38M30.97M72.27M
Long-term Debt249K24.53M40.09M40.72M76.33M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0025.35M58.2M40.65M
Total Non-current Liabilities2.51M26M65.96M99.46M116.98M
Total Liabilities21.1M47.66M92.34M130.43M189.25M
Common Stock19K20K3K4K8K
Retained Earnings(663.71M)(737.52M)(824.89M)(955.53M)(1.16B)
Accumulated OCI34K013K05.23M
Other Stockholders Equity00000
Minority Interest00000
Total Equity87.56M47.39M57.37M(28.89M)57.2M
Total Debt3.18M27.07M41.56M42.25M76.87M
Net Debt(18.07M)(47.87M)(36.35M)(46.56M)(128.13M)

Verastem, Inc.

NASDAQ:VSTM

Intrinsic Alpha fair value

Locked

Current Price

$6.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.